Privileged Diazepine Compounds and Their Emergence as Bromodomain Inhibitors
Open accessThe DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Abstract
Chemical compounds built on a diazepine scaffold have recently emerged as potent inhibitors of the acetyl-lysine binding activity of bromodomain-containing proteins, which is required for gene transcriptional activation in cancer and inflammation. Not only have these chemical compounds validated bromodomains as attractive epigenetic drug targets, but they have also brought to the forefront another application of the diazepine, which had already been regarded as a versatile chemical scaffold in rational drug design. This article reviews the success of diazepine compounds as therapeutic agents and examines the unique chemical and geometric features of this privileged scaffold that make it an excellent template for developing potent and selective molecules that control bromodomain-related gene expression in human diseases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Selective inhibition of BET bromodomains
Filippakopoulos, P., Qi, J., Picaud, S., Shen, Y., Smith, W. B., Fedorov, O., Morse, E. M., Keates, T., Hickman, T. T., Felletar, I., et al. (2010) · Nature · doi:10.1038/nature09504 · Cited by 4,262 · cited 6×
“For example, one of the main structural features of JQ1 is a bulky t-butyl ester group attached at C3 (Figure 4C), which is cited as the reason that JQ1 shows little activity against the BZD allosteric binding site on the GABAA receptor (Filippakopoulos et al., 2010).”
BackgroundMethodInfluentialRNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia
Zuber, J., Shi, J., Wang, E., Rappaport, A. R., Herrmann, H., Sison, E. A., Magoon, D., Qi, J., Blatt, K., Wunderlich, M., et al. (2011) · Nature · doi:10.1038/nature10334 · Cited by 1,870 · cited 1×
“…BRD4, have recently been shown to play an important role in the pathways that cause multiple types of cancer, including acute myeloid leukemia (Zuber et al., 2011), mixed lineage leukemia (Dawson et al., 2011), multiple myeloma (Mertz et al., 2011), and an aggressive form of squamous…”
BackgroundStructure and ligand of a histone acetyltransferase bromodomain
Dhalluin, C., Carlson, J. E., Zeng, L., He, C., Aggarwal, A. K., Zhou, M.-M., & Zhou, M.-M. (1999) · Nature · doi:10.1038/20974 · Cited by 1,732 · cited 2×
“First reported as the acetyl-lysine binding domain in the transcriptional co-activator PCAF in 1999 (Dhalluin et al., 1999), the bromodomain functions to bind acetylated lysines in histones and nonhistone proteins, thereby controlling acetylation-mediated protein-protein interactions in gene…”
BackgroundSelf-citationSuppression of inflammation by a synthetic histone mimic
Nicodeme, E., Jeffrey, K. L., Schaefer, U., Beinke, S., Dewell, S., Chung, C.-W., Chandwani, R., Marazzi, I., Wilson, P., Coste, H., et al. (2010) · Nature · doi:10.1038/nature09589 · Cited by 1,563
Privileged scaffolds for library design and drug discovery
Welsch, M. E., Snyder, S. A., & Stockwell, B. R. (2010) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2010.02.018 · Cited by 1,509 · cited 1×
“…that is important to agonist binding—receptor isoforms rely on many different residues to interact with different functional groups on BZD ligands (Amin et al., 1997; Buhr et al., 1996, 1997; Kucken et al., 2000; Pritchett and Seeburg, 1991; Richter et al., 2012; Wieland and Lüddens, 1994).”
BackgroundEpigenetic protein families: a new frontier for drug discovery
Arrowsmith, C. H., Bountra, C., Fish, P. V., Lee, K., & Schapira, M. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3674 · Cited by 1,327 · cited 1×
“Inhibitors of bromodomain-containing proteins are a part of the extensive pipeline of epigenetic modulators that has the potential to bring advanced, targeted treatments to patients in the near future (Arrowsmith et al., 2012; Dawson et al., 2012; DeWoskin and Million, 2013; Kelly et al., 2010).”
BackgroundBenzodiazepine actions mediated by specific γ-aminobutyric acidA receptor subtypes
Rudolph, U., Crestani, F., Benke, D., Brünig, I., Benson, J. A., Fritschy, J.-M., Martin, J. R., Bluethmann, H., & Möhler, H. (1999) · Nature · doi:10.1038/44579 · Cited by 1,172
Molecular and neuronal substrate for the selective attenuation of anxiety
Löw, K., Crestani, F., Keist, R., Benke, D., Brünig, I., Benson, J. A., Fritschy, J.-M., Rülicke, T., Bluethmann, H., Möhler, H., et al. (2000) · Science · doi:10.1126/science.290.5489.131 · Cited by 946
McKernan, R. M., Rosahl, T. W., Reynolds, D. S., Sur, C., Wafford, K. A., Atack, J. R., Farrar, S., Myers, J., Cook, G., Ferris, P., et al. (2000) · Nature Neuroscience · doi:10.1038/75761 · Cited by 944
Beyond classical benzodiazepines: novel therapeutic potential of GABAA receptor subtypes
Rudolph, U., & Knoflach, F. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3502 · Cited by 733 · cited 1×
“…and through the use of BZD inhibition in the altered mice and in wild-type mice, were able to determine the activities controlled by each a subtype (Crestani et al., 2001, 2002; Löw et al., 2000; McKernan et al., 2000; van Rijnsoever et al., 2004; Rudolph et al., 1999; Rudolph and Knoflach, 2011).”
MethodPlace your BETs: the therapeutic potential of bromodomains
Prinjha, R. K., Witherington, J., & Lee, K. (2012) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2011.12.002 · Cited by 197 · cited 1×
“…that is important to agonist binding—receptor isoforms rely on many different residues to interact with different functional groups on BZD ligands (Amin et al., 1997; Buhr et al., 1996, 1997; Kucken et al., 2000; Pritchett and Seeburg, 1991; Richter et al., 2012; Wieland and Lüddens, 1994).”
BackgroundStahl, S. M. (2002) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v63n0901 · Cited by 88 · cited 2×
“2 Chemistry & Biology 21, May 22, 2014 a2014 Elsevier Ltd All rights used, and are being actively studied in the search for selective, symptom-specific therapeutics (Griebel and Holmes, 2013; Nash and Nutt, 2007; Skolnick, 2012; Stahl, 2002).”
Background
Cited by
Vitaku, E., Smith, D. T., & Njardarson, J. T. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm501100b · Cited by 6,418
Qin, C., Hu, Y., Zhou, B., Fernandez-Salas, E., Yang, C.-Y., Liu, L., McEachern, D., Przybranowski, S., Wang, M., Stuckey, J., et al. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b00506 · Cited by 281
“We next synthesized 32 and 33 by converting the 3-carbonyl group in the thalidomide moiety of 29 and 30 to a methylene group in an e ff ort to further improve potency.”
BackgroundMethodProtein–Protein Interaction Modulators for Epigenetic Therapies
(2018) · Advances in Protein Chemistry and Structural Biology · doi:10.1016/bs.apcsb.2017.06.002 · Cited by 31
Avendaño, C., & Menéndez, J. C. (2023) · Medicinal Chemistry of Anticancer Drugs · doi:10.1016/b978-0-12-818549-0.00019-4 · Cited by 4
Metadata
- Authors
- Smith, S. G., Sanchez, R., & Zhou, M.-M.
- Venue
- Chemistry & Biology
- Publisher
- Elsevier BV
- Published
- 2014-05
- Volume
- 21
- Issue
- 5
- Pages
- 573-583
- ISSN
- 1074-5521 (ISSN-L)
- OpenAlex
- W2085538883
- Cited by
- 81
- References
- 12
- FWCI
- 3.29
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.